Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.
The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.
Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.